About LAPELGA

LAPELGA is a medication used to stimulate the production of white blood cells in patients undergoing chemotherapy. It contains the active ingredient PEGFILGRASTIM, a recombinant DNA-derived human granulocyte-macrophage colony-stimulating factor (GM-CSF) analog.

Key Benefits & Uses

Reduces the incidence of febrile neutropenia (a potentially life-threatening complication of chemotherapy) in patients with non-myeloid malignancies.
Helps to accelerate the recovery of neutrophil counts in patients receiving chemotherapy.
May be used in combination with other medications to reduce the risk of infection in patients undergoing chemotherapy.

Active Ingredient & Action

PEGFILGRASTIM works by stimulating the production of granulocytes and macrophages in the bone marrow, which helps to increase the body's ability to fight infection. It does this by binding to specific receptors on the surface of hematopoietic progenitor cells, triggering a cascade of cellular responses that ultimately lead to the production of mature white blood cells.

Important Notes

LAPELGA should only be used under the guidance of a qualified healthcare professional. Patients should be closely monitored for signs of infection, and the medication should be administered according to the recommended dosing schedule. Common side effects of LAPELGA may include bone pain, fatigue, and injection site reactions.